Reviewing Rezolute (NASDAQ:RZLT) & ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA) and Rezolute (NASDAQ:RZLT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares ADMA Biologics and Rezolute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	28.80%	37.52%	27.87%
Rezolute	N/A	-64.81%	-59.37%

Institutional and Insider Ownership

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Comparatively, 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ADMA Biologics and Rezolute”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17 million	7.18	$146.93 million	$0.60	25.65
Rezolute	N/A	N/A	-$74.41 million	($0.93)	-3.34

ADMA Biologics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ADMA Biologics and Rezolute, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	1	0	2	3.33
Rezolute	1	5	5	0	2.36

ADMA Biologics presently has a consensus price target of $32.00, suggesting a potential upside of 107.93%. Rezolute has a consensus price target of $7.63, suggesting a potential upside of 145.18%. Given Rezolute’s higher probable upside, analysts clearly believe Rezolute is more favorable than ADMA Biologics.

Risk and Volatility

ADMA Biologics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Summary

ADMA Biologics beats Rezolute on 9 of the 13 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.